Evidence map›Paper›PMID 33602234›Full record

ArticleJournal of neuroinflammation2021

Small-molecule antagonist of VLA-4 (GW559090) attenuated neuro-inflammation by targeting Th17 cell trafficking across the blood-retinal barrier in experimental autoimmune uveitis.

Yi Hsing Chen, Malihe Eskandarpour, Xiaozhe Zhang, Grazyna Galatowicz, John Greenwood, Sue Lightman, Virginia Calder

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroinflammation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Enhanced ROS Production and Mitochondrial Metabolic Shifts in CD4International journal of molecular sciences · 2024
    Article
  2. Article
  3. Article
  4. Long-lived autoreactive memory CD4FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023
    Article
  5. Article
  6. Article
  7. Review
  8. Adhesion Molecule Targeted Therapy for Non-Infectious Uveitis.International journal of molecular sciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Yi Hsing ChenUCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK.
Malihe EskandarpourUCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK.
Xiaozhe ZhangUCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK.
Grazyna GalatowiczUCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK.
John GreenwoodUCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK.
Sue LightmanUCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK.
Virginia CalderUCL Institute of Ophthalmology, University College London, 11-43 Bath Street, London, EC1V 9EL, UK. v.calder@ucl.ac.uk.ORCID http://orcid.org/0000-0003-1422-2926
University College London · GBChang Gung University · TWMoorfields Eye Hospital · GBUCL Biomedical Research Centre · GBUniversity College Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe integrin VLA-4 (α4β1) plays an important role in leukocyte trafficking. This study investigated the efficacy of a novel topical α4β1 integrin inhibitor (GW559090, GW) in a mouse model for non-infectious posterior uveitis (experimental autoimmune uveitis; EAU) and its effect on intraocular leukocyte subsets.

methodsMice (female; B10.RIII or C57Bl/6; aged 6-8 weeks) were immunized with specific interphotoreceptor retinoid-binding protein (IRBP) peptides to induce EAU. Topically administered GW (3, 10, and 30 mg/ml) were given twice daily either therapeutically once disease was evident, or prophylactically, and compared with vehicle-treated (Veh) and 0.1% dexamethasone-treated (Dex) controls. Mice were sacrificed at peak disease. The retinal T cell subsets were investigated by immunohistochemistry and immunofluorescence staining. The immune cells within the retina, blood, and draining lymph nodes (dLNs) were phenotyped by flow cytometry. The effect of GW559090 on non-adherent, adherent, and migrated CD4

resultsThere was a significant reduction in clinical and histological scores in GW

conclusionsThis α4β1 integrin inhibitor may exert a modulatory effect in EAU progression by selectively blocking Th17 cell migration across the blood-retinal barrier without affecting systemic CD4

Indexed as

AnimalsAutoimmune DiseasesBlood-Retinal BarrierCells, CulturedDose-Response Relationship, DrugDrug Delivery SystemsFemaleHumansIntegrin alpha4beta1MiceMice, Inbred C57BLMice, TransgenicPhenylalaninePiperidinesTh17 CellsUveitisGW559090Integrin alpha4beta1PhenylalaninePiperidinesExperimental autoimmune uveitisInflammatory monocytes/macrophagesIntegrin (α4β1Leukocyte migrationTh17 cellsUveitisVLA-4)

Identifiers

PMID33602234
PMCPMC7893745
OpenAlexW3130512165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.